Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society

Pimentel, Matthew A.; Li, May M; Noe, Megan H.; Latour, Emile; Seminario‐Vidal, Lucia; Greiling, Teri M.; Shinkai, Kanade; Hamilton, A.; Alavi, Afsáneh; Bolognia, Jean L.; Cowen, Edward W.; Domínguez, Arturo R.; Fernandez, Anthony P.; Fivenson, David P.; Huang, William W.; Madigan, Lauren M.; Mauskar, Melissa M.; Means, Alexander D.; Nelson, Caroline A.; Patsatsi, Aikaterini; Pugliese, Douglas J.; Rojek, Nathan W; Rosenbach, Misha; Smith, Gideon P.; Swerlick, Robert A.; Heffernan, Michael; Mostaghimi, Arash; Ortega‐Loayza, Alex G.

doi:10.1093/bjd/ljac137

Cited by 5 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Domains to specifically assess the impact of PG have been established, one of which is pain [ 99 ]. Pain remains an important aspect to take into consideration when addressing the severity of PG [ 100 ]. Several instruments have been used to assess quality of life including pain, though there none are specific to PG.…”

Section: Adjunctive Managementmentioning

confidence: 99%

Pyoderma Gangrenosum: Treatment Options

Dissemond,

Marzano,

Hampton

et al. 2023

Drugs

View full text Add to dashboard Cite

Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.

show abstract

Section: Adjunctive Managementmentioning

confidence: 99%

Pyoderma Gangrenosum: Treatment Options

Dissemond,

Marzano,

Hampton

et al. 2023

Drugs

View full text Add to dashboard Cite

show abstract

“…These findings build on prior data suggesting that ulcer size at initial presentation is the most important predictor of healing time, and that ulcer number influences disease severity. 4 , 5 …”

mentioning

confidence: 99%